The insulin sensitizer pioglitazone improves the deterioration of ischemic preconditioning in type 2 diabetes mellitus rats

International Heart Journal

Volumn 48, Issue 5, 2007, Pages 623-635

  Sasaki, Hideki ^a   Ogawa, Kazuhiko ^a   Shimizu, Mitsuyuki ^a   Mori, Chikara ^a   Takatsuka, Hisashi ^a   Okazaki, Fumiko ^a   Kawai, Makoto ^a   Taniguchi, Ikuo ^a   Mochizuki, Seibu ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Insulin sensitizer; Ischemia; Ischemic preconditioning; Otsuka Long Evans Tokushima Fatty (OLETF) rat; Pioglitazone; Reperfusion arrhythmias; Type 2 diabetes mellitus

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; LACTIC ACID; PIOGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; GLUCOSE METABOLISM; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HEART PERFUSION; HEART VENTRICLE TACHYCARDIA; INCIDENCE; INSULIN SENSITIVITY; ISCHEMIC PRECONDITIONING; ISOLATED HEART; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OTSUKA LONG EVANS TOKUSHIMA FATTY RAT; PRIORITY JOURNAL; RAT;

ANIMALS; ARRHYTHMIAS, CARDIAC; CORONARY CIRCULATION; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; HEMOGLOBIN A, GLYCOSYLATED; HYPOGLYCEMIC AGENTS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MYOCARDIAL REPERFUSION INJURY; RATS; RATS, INBRED OLETF; THIAZOLIDINEDIONES;

EID: 36749021548     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.48.623     Document Type: Article

References (66)

1. Jaffe AS, Spadaro JJ, Schechtman K, Roberts R, Geltman EM, Sobel BE. Increased congestive heart failure after Myoccardial infarction of modest extent in patients with diabetes mellitus. Am Heart J 1984; 108: 31-7.
2. Mak KH, Moliterno Di, Granger CB, et al. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol 1997; 30: 171-9.
3. Haffner SM, Lehto S, Ronnemaa T, Pyorala Y, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infraction. N Engl J Med 1998; 339: 229-34.
4. 2+ metabolism. Circ Res 1988; 62: 931-40.
5. Khandoudi N, Bernard M, Cozzone P, Feuvray D. Mechanisms of intracellular pH regulation during post-ischemic reperfusion of diabetic rat hearts. Diabetes 1995; 44: 196-202.
6. Gamble J, Lopaschuk GD. Glycolysis and glucose oxidation during reperfusion of ischemic hearts from diabetic rats. Biochem Biophys Acta 1994; 1225: 191-9.
7. Lopaschuk GD, Saddik M, Barr R, Huang L, Barker CC, Muzyka RA. Effects of high levels of fatty acicb on functional recovery of ischemic hearts from diabetic rats. Am J Physiol 1992; 263: E1046-53.
8. Bouchard JF, Lamontagne D. Protection afforded by preconditioning to the diabetic heart against ischemic injury. Cardiovasc: Res 1998; 37: 82-90.
9. Tatsumi T, Matoba S, Kobara M, et al. Energy metabolism after ischemic preconditioning in streptozotocin-induced diabetic rat hearts. J Am Coll Cardiol 1998; 31: 707-15.
10. Feuvray D. The regulation of intracellular pH in the diabetic myocardium. Cardiovasc: Res 1997; 34: 48-54. (Review)
11. Kusuoka H. Matsuda, S, Ishikawa M, et al. Diflerence in the mechanisms for compensating ischemic acidosis in diabetic rat hearts. J Mol Cell Cardiol 1998; 30: 1643-9.
12. + exchanger protects diabetic and non-diabetic hearts from ischermc: injury insight into altered susceptibility of diabetic heart to ischemic injury. J Mol Cell Cardiol 1999; 31:785-97.
13. Liu Y, Thornton JD, Cohen MV, Downey JM, Schaffer SW. Streptozotocin-induced non-insulin-dependent diabetes protects the heart from infarction. Circulation 1993; 88: 1273-8.
14. Mozaffari MS, Schaffer SW. Effect of hypertension and hypertension-glucose intolerance on myocardial ischemic injury. Hypertension 2003; 42: 1042-9.
15. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74: 1124-36.
16. Katakam PV, Jordan JE, Snipes JA, Tulbert CD, Miller AW, Busija DW. Myocardial preconditioning against ischemia-reperfusion injury is abolished in Zucker obese rats with insulin resistance. Am J Physiol Regul Integr Comp Physiol 2007; 292: R920-6.
17. Hassouna A, Loubani M, Matata BM, Fowler A, Standen NB, Galinanes M. Mitochondrial dysfunction as the cause of the failure to precondition the diabetic human myocardium. Cardiovase Res 2006; 69: 450-8.
18. Tsang A, Hausenloy DJ, Mocanu MM, Carr RD, Yellon DM. Preconditioning the diabetic heart the importance of Akt phosphorylation. Diabetes 2005; 54: 2360-4.
19. Ravingerova T, Stetka R, Pancza D, Ulicna O, Ziegelhoffer A, Styk J. Susceptibility to ischemia-induced arrhythmias and the effect of preconditioning in the diabetic rat heart. Physiol Res 2000; 49: 607-16.
20. Kawano K, Hirashima T, Mori S, Shitoh Y, Kurosumi M, Natori T. Spontaneous long-term hyperglycemic rat with diabetic complications Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes 1992; 41: 1422-8.
21. Maddaford TG, Russell JC, Pierce GN. Postischemic cardiac performance in the insulin-resistant JCR:LA-cp rat. Am J Physiol 1997; 273: H1187-92.
22. Yue TL, Bao W, Gui JL, et al. Rosiglitazone treatment in Zucker diabetic Fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/reperfusion-induced myocardial injury. Diabetes 2005; 54: 554-62.
23. Dormandy J, Charbonnel B, Eckland DJ, et al. Secondaiy prevention of macrovascular events in patients with type 2 diabetes in the PROactive Shidy (PROactive pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet 2005; 366: 1279-89.
24. Neely JR, Rovetto MJ, Whitmer JT, Morgan BE. Effects of ischemia on function and metabolism of the isolated working rat heart. Am J Physiol 1973; 225: 651-8.
25. Sakomoto J, Miura T, Tsuchida A, Fukuma T, Hasegawa T, Shimamoto K. Reperfusion arrhythmias in the murine heart: their characteristics and alteration after ischemic preconditioning. Basic Res Cardiol 1999; 94: 489-95.
26. Taniguchi Y, Ooie T. Takahashi N, et al. Pioglitazone but not glibenclamide improves cardiac expression of heat shoc protein 72 and tolerance against ischemia/reperfusion injury in the heredity insulin-resistarit rat. Diabetes 2006; 55: 2371-8.
27. Spray DC, Bennett MV. Physiology and pharmacology of gap junctions. Ann Rev Physiol 1985; 47: 281-303. (Review)
28. + exchange. Circ Res 1990; 66: 1156-9.
29. Manning AS, Coltart DJ, Hearse DJ. Ischemia and reperfusion-induced arrhythmias in the rat. Effects of xanthine oxidase inhibition with allopurinol. Circ Res 1984; 55: 545-8.
30. Bernier M, Hearse DJ, Manning AS. Reperfusion-induced arrhythmias and oxygen-derived free radicals. Studies with "anti-free radical" interventions and a free radical-generating system in the isolated perfused rat heart. Circ Res 1996; 58: 331-40.
31. Grech ED, Dodd NJ, Bellamy CM, Perry RA, Morrison WL, Ramsdale DR. Free-radical generation during angioplasty reperfusion for acute myocardial infarction. Lancet 1993; 341: 990-1.
32. Heyndrickx GR, Vatner SF, Wijins et al. Stunning, hibernation, and preconditioning. Clinical Pathophysiology of Myocardial Ischemia. Philadelphia, USA: Lippincott-Raven; 1997.
33. Connaughton M, Hearse DJ. Three questions about preconditioning. Basic Res Cardiol 1996; 91: 12-5.
34. Kasamaki Y, Guo AC, McDonald TF. Protection by hypoxic preconditioning against hypoxia-reoxygenation injury in guinea-pig papillary muscles. Cardiovasc Res 1997; 34: 313-22.
35. + production. Cardioangiology 1993; 34: 590-6 (in Jpn).
36. + production in preconditioning for the prevention of reperfusion-induced arrhythmias. J Clin Exp Med 1992; 162: 953-4 (in Jpn with Eng abst).
37. Osada M, Sato T, Komori S, Tamura K. Protective effect of preconditioning on reperfiision induced ventricular arrhythmias of isolated rat hearts. Caidiovasc Res 1991; 25: 441-4.
38. Ishibara M, Inoue I, Kawagoe T, et al. Diabetes mellitus prevents ischemic preconditioning in patients with a first acute anterior wall myocardial irdaixton. J Am Coll Cardiol 2001; 38: 1007-11.
39. + channels in cardiac muscle. Nature 1983; 305: 147-8.
40. + channels and PKC in anti-infarct tolerance afforded by adenosine A1 receptor activation. J Am Coll Cardiol 2000; 35: 238-45.
41. del Valle HF, Lascano EC, Negroni JA. Crottogini AJ. Absence of ischemic preconditioning protection in diabetic sheep hearts: role of sarcolemmal KATP channel dysfunction. Mol Cell Biochem 2003; 249: 21-30.
42. Smith JM, Wahler GM. ATP-sensitive potassium channels are altered in ventricular myocytes from diabetic rats. Mol Cell Biochem 1996; 158: 43-51.
43. + current in guinea pig ventricular myocytes. Circ Res 1990; 67: 1124-33.
44. Allison TB, Brutting SP, Crass MF 3rd, Eliot RS, Shipp JC. Reduced high-energy phosphate levels in rat hearts. I. Edects of alloxan diabetes. Am J Physiol 1976; 230: 1744-50.
45. Jimenez-Navarro M, Gomez-Doblas JJ, Hernandez Garcia JM, et al. Does angina pectoris the week before protect against first acute myocardial infintion in patients with diabetes mellitus? Am J Cardiol 2002, 90: 160-2.
46. Kristiansen SB, Lofgren B, Stothup NB et al. Ischaemic preconditioning does not protect the heart in obese and lean animal models of type 2 diabetes. Diabetologia 2004; 47: 1716-21.
47. Tosaki A, Engelman DT, Engelman W, Das DK. The evolution of diabetic response to ischemia/reperfusion and preconditioning in isolated working rat hearts. Cardiovasc Res 1996; 31: 526-36.
48. Ravingerova T, Stetka R, Volkovova K, et al. Acute diabetes modulates response to ischemia in isolated rat heart. Mol Cell Biochem 2000; 210: 143-51.
49. Ebel D, Mullenheim J, Frassdorf J, et al. Effect of acute hyperglycemia and diabetes mellittus with and without short-term insulin treatment on myocardial ischaermic late preconditioning in the rabbit heart in vivo. Pflugers Arch 2003; 446: 175-82.
50. Marfella R, Di Filippo C, Esposito K, et al. Absence of inducible nitric oxide synthase reduces myocardial damage during ischemia reperfusion in streptozotocin-induced hyperglycemic mice. Diabetes 2004; 53: 454-62.
51. Kersten JR, Toller WG, Gross ER, Pagel PS, Warltier DC. Diabetes abolishes ischemic preconditioning: role of glucose, insulin, and osmolality. Am J Physiol Heart Circ Physiol 2000; 278: H1218-24.
52. Tonelli J, Li W, Kishore P, et al. Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes. Diabetes 2004; 53: 1621-9.
53. Tanaka T, Yamamoto J, Iwasaki S, et al. Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci USA 2003; 100: 15924-9.
54. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004; 351: 1406-18. (Review)
55. Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nalure 2000; 405: 421-4. (Review)
56. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity Nat Med 2001; 7: 941-6.
57. Kubota N, Terauchi Y, Kubota T, et al. Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways. J Biol Chem 2006; 281: 8748-55.
58. Iwaki M, Matsuda M, Maeda N, et al. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 2003; 52: 1655-63.
59. Hirose H, Kawai T, Yamamoto Y, et al. Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metabolism 2002; 51: 314-7.
60. Hanefeld M. Marx N, Pfutzner A, et al. Anti-inflammatory effects of pioglitazone and/or sirrivastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study. J Am Coll Cardiol 2007; 49: 290-7.
61. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391: 82-6.
62. Hetzel J, Balletshofer B, Rittig K, et al. Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers. Arterioscler Thromb Vasc Biol 2005; 25: 1804-9.
63. Wang N, Verna L, Chen NG, et al. Constitutive activation of peroxisome proliferator-activated receptor-gamma suppresses pro-inflammatory adhesion molecules in human vascular endothelial cells. J Biol Chem 2002; 277: 34176-81.
64. Sourij H, Zweiker R, Wascher TC. Effects of pioglitazone on endothelial function, insulin sensitivity, and glucose control in subjects with coronary artery disease and new-onset type 2 diabetes. Diabetes Care 2006; 29: 1039-45.
65. Sidell RJ, Cole MA, Draper NJ, Desrois M, Buckingham RE, Clarke K. Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the zucker Fatty rat heart. Diabetes 2002; 51: 1110-7.
66. Shibata R, Sato K, Pimentel DR, et al. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med 2005; 11: 1096-103.